Cancer Vaccine Institute News

On October 30, the FDA granted accelerated approval to Voceryq, the first-ever plasmid DNA-based immunotherapy, developed by Inovio Pharmaceuticals. The treatment delivers two plasmids to help the immune system target cells infected with human papillomavirus (HPV), which are responsible for recurrent respiratory papillomatosis (RRP). The FDA’s approval marks an important milestone for DNA-based therapeutics and could help advance research in this field. Cancer Vaccine Institu

On the Cancer Research Frontier is a series spotlighting the scientists, doctors, nurses, patients, and philanthropists at the Cancer Vaccine Institute. Join us in meeting the brilliant minds behind our cancer vaccines and immunotherapies as they share their professional journeys and personal stories. At 5:30 AM, after a one-hour commute, Cancer Vaccine Institute (CVI) Lab Manager and Research Scientist III Erin Rodmaker is already at the preclinical lab. While much of Seattl

On October 9, the energy of Husky football carried a message bigger than the game itself: building a future where cancer can no longer claim the lives of loved ones. Cancer Vaccine Institute (CVI) patients, members, and cancer survivors lined the tunnel as the Huskies took the field, bringing together two communities united by this shared mission. Through Huskies for a Cure, UW Athletics and the Husky community turned the spirit of competition into meaningful support for canc

Breast cancer is one of the most common cancers and the second leading cause of cancer-related death among women. While advances in targeted therapies have improved patient outcomes for several breast cancer subtypes, metastatic triple-negative breast cancer (TNBC) remains one of the most challenging forms of the disease to treat. Although immune checkpoint inhibitors (ICIs) combined with chemotherapy have improved survival for some patients with metastatic TNBC, this benefit

Dr. Nora Disis, Director of the Cancer Vaccine Institute (CVI), spoke with FOX 13’s Claire Anderson to share encouraging clinical trial results and discuss the growing promise of breast cancer vaccines. The CVI is developing breast cancer vaccines that can program the body’s own immune system to recognize and kill breast cancer cells. These immune cells are capable of remaining in the body for years, providing long-term protection from cancer coming back. Dr. Disis explains,